Ligand Pharmaceuticals Incorporated LGND
NASDAQ · United States · Health Technology
$302.74-9.63 (-3.08%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
| Quarter | Report date | Actual EPS | Estimated EPS | EPS surprise | Actual revenue | Revenue surprise | Price reaction |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-08-06 | 2.37 | 2.01 | +17.9% | $63.69M | +3.9% | -3.1%$302.57→$293.15 |
| Q1 2026 | 2026-05-07 | -0.67 | 0.98 | -168.4% | — | — | -4.8%$232.55→$221.41 |
| Q4 2025 | 2026-02-26 | 2.02 | 1.50 | +34.7% | — | — | +3.6%$191.39→$198.31 |
| Q3 2025 | 2025-11-06 | 5.68 | 1.09 | +421.1% | — | — | +6.4%$190.38→$202.48 |
| Q4 2024 | 2025-02-27 | 1.27 | 1.19 | +6.7% | — | — | — |
| Q2 2024 | 2024-08-06 | 1.40 | 1.06 | +32.1% | — | — | — |
| Q1 2024 | 2024-05-08 | 1.20 | 0.83 | +44.6% | — | — | — |
| Q4 2023 | 2024-02-27 | 1.38 | 0.66 | +109.1% | — | — | — |
The price reaction is the change from the last close before the announcement date to the first close after it - the report may land before the open, during the session or after the close, so this window covers all three. Not investment advice.